Eli Lilly and Company (LLY) Stock Chart

NYSE
$1,208.74+0.00 (+0.00%)After hours

View the Eli Lilly and Company stock chart with market data, key statistics, volume, financial metrics, latest news, and exportable historical data.

Source
Nasdaq Real Time Price
Quote Time
Oct 14, 2026, 9:19 PM UTC
Delay
20 min source-reported delay

Market data is for research and educational use only, not investment advice. Quotes may be delayed depending on the source and exchange; verify important prices with your broker or data provider.

Read the LLY trend first

Use the range controls to compare short-term moves with the longer-term Eli Lilly and Company stock chart. A move that looks large on 1D can look routine on a 1Y or 5Y chart.

Check price with volume

Volume helps show whether a move happened with broad participation or thin trading. Compare recent bars with the average volume and news context before drawing conclusions.

Verify before acting

This page is built for research and education. Quotes, analyst fields, and news can be delayed or revised, so verify important prices with your broker or primary data provider.

Key Statistics

Previous Close$1,166.51
Open$1,177.87
Day Range$1,174.24 — $1,216.71
52 Wk Range$783.85 — $1,292.65
Volume3,147,029
Avg Volume2,453,768
Market Cap1.08T
P/E (TTM)40.58
P/E (Fwd)25.46
EPS (TTM)$29.79
Dividend Yield0.59%
Beta0.45
50 Day Avg$1,175.55
200 Day Avg$1,077.50
Shares Out891.74M
PEG Ratio1.13
Price/Book31.81

Financial Metrics

Revenue
79.67B
Revenue Growth
47.70%
Gross Margin
83.40%
Operating Margin
54.22%
Profit Margin
33.53%
Return on Equity
102.29%
Total Cash
8.95B
Total Debt
54.91B
Free Cash Flow
11.07B
Analyst Target
$1,328.05
Analyst Consensus
Buy
Analyst Opinions
30

About Eli Lilly and Company

Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
50,000
Headquarters
Indianapolis, IN, United States
Website
lilly.com
CEO
Mr. David A. Ricks

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Related Charts

Data Definitions

Previous close

The most recent prior regular-session close reported by the market data source.

Day range

The source-reported high and low for the current or most recent trading session.

Volume

The number of shares, units, contracts, or asset quantity reported as traded during the period.

Moving averages

The 50-day and 200-day averages smooth recent prices to give quick trend context.

Market cap

A company or fund size estimate based on price and shares outstanding when source data is available.

P/E ratio

Price divided by earnings per share. It is most useful when compared with peers and growth expectations.